期刊文献+

胰岛素联合用药治疗2型糖尿病的临床研究 被引量:1

Clinical Research about Intensification Therapy of Trypsin with Drug Combination on Treatment of Type 2 Diabetes
下载PDF
导出
摘要 目的探讨两种胰岛素联合用药强化治疗方案治疗2型糖尿病的临床效果。方法将2008年1月至2009年5月间在佛山市南海区第二人民医院住院治疗的2型糖尿病患者72例随机分为A组、B组和C组,A组应用诺和锐30联用拜唐平,B组应用诺和灵30R和二甲双胍,C组单纯应用诺和灵30R,评估3组治疗效果。结果 A组、B组治疗后FPG、2hPG、HbA1C明显低于C组(P<0.05)。A组与B组治疗后FPG、2hPG、HbA1c分别比较差异无统计学意义(P>0.05)。3组治疗后BMI指标相互比较差异无统计学意义(P>0.05)。A组、B组总有效率明显高于C组,两组分别比较差异具有统计学意义(P<0.05)。A组总有效率与B组比较差异无统计学意义(P>0.05)。A组、B组胰岛素用量明显少于C组,两组分别比较差异具有统计学意义(P<0.05)。不良事件发生率A组、B组明显低于C组(P<0.05),A组发生率与B组比较差异无统计学意义(P>0.05)。结论两种强化治疗方案均能有效地控制血糖,值得临床广泛应用。 Objective To investigate the effect of intensification therapy of two trypsins with drug combination on treatment of type 2 diabetes.Method The 72 cases with type 2 diabetes in the second people's hospital of Nanhai district from January in 2008 to may in 2009 were divided into the A group,B group and C group,the A group received the treatment of novorapid 30 combined with glucobay,the B group received the treatment of novolin 30R and diformin,and the C group received the treatment of novolin 30R.Results The level of FPG,2hPG and HbA 1 C after treatment in the A group and B group was lower than those in C group,and there was significant difference in them respectively(P〈0.05).There was on significant difference respectively on the level of FPG,2hPG and HbA 1 C after treatment in the A group and B group(P〉0.05).There was no significant difference in them respectively about level of BMI after treatment(P〉0.05).The total effective rate in A group and B group was higher than that in C group and there was significant difference in them respectively(P〈0.05).The total effective rate in B group was same to that in A group,and there was no significant difference in them respectively(P〉0.05).The usage amount of trypsin in A group and B group was lower than that in C group and there was significant difference in them respectively(P〈0.05).The bad incident in A group and B group was lower than that in C group and there was significant difference in them respectively(P〈0.05).Conclusion The two kinds of intensification therapy can control the level of blood sugar well,so they are worth being used.
出处 《中国医药指南》 2010年第22期32-34,共3页 Guide of China Medicine
关键词 拜唐平 诺和锐30 二甲双胍 诺和锐30R 2型糖尿病 Glucobay Novorapid 30 Diformin Novolin 30R
  • 相关文献

参考文献4

二级参考文献6

  • 1孙丽萍,宋协斌.老年2型糖尿病低血糖33例分析[J].中国误诊学杂志,2006,6(18):3607-3608. 被引量:1
  • 2David M ,Nathan,John B ,et al. Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy[ J]. Diabetes Care ,2008,31 ( 12 ) : 1 - 11.
  • 3UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonyluresa or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS33 ) [ J ]. Lancet, 1998,352 (9131 ) : 837 - 853.
  • 4Yki-Jarvinen H, Kauppinen-Makelin R,Tiikkainen M,et al. Insulin glargine or NPH combined with mefformin in type 2 diabetes:the LAN- MET study[J]. Diabetologia,2006,49(3) :442 -451.
  • 5Birkeland KI. Improving glycaemie control with current therapies[ J ]. Diabet Med,1998,15(Suppl 4) :13 - 19.
  • 6龙盛双,赵源娟,李建国.2型糖尿病低血糖诱因分析及干预[J].遵义医学院学报,2007,30(3):332-333. 被引量:7

共引文献190

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部